183 related articles for article (PubMed ID: 37120329)
21. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
[TBL] [Abstract][Full Text] [Related]
23. Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease.
Ramírez-Vélez R; García-Hermoso A; Correa-Rodríguez M; Izquierdo M
Pediatr Res; 2022 Mar; 91(4):912-920. PubMed ID: 33846557
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.
Lukenda Zanko V; Domislovic V; Trkulja V; Krznaric-Zrnic I; Turk-Wensveen T; Krznaric Z; Filipec Kanizaj T; Radic-Kristo D; Bilic-Zulle L; Orlic L; Dinjar-Kujundzic P; Poropat G; Stimac D; Hauser G; Mikolasevic I
Diabetes Obes Metab; 2020 Nov; 22(11):2097-2106. PubMed ID: 32613718
[TBL] [Abstract][Full Text] [Related]
28. Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis.
Cai C; Song X; Chen X; Zhou W; Jin Q; Chen S; Ji F
Can J Gastroenterol Hepatol; 2021; 2021():8859338. PubMed ID: 33542909
[TBL] [Abstract][Full Text] [Related]
29. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
[TBL] [Abstract][Full Text] [Related]
30. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
31. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
32. Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease.
Wong YJ; Urias E; Song MW; Goyal T; Tay WX; Han NX; Loo JH; Qiu TY; Wijarnpreecha K; Chan YH; Chen VL
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37738409
[TBL] [Abstract][Full Text] [Related]
33. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.
Tapper EB; Challies T; Nasser I; Afdhal NH; Lai M
Am J Gastroenterol; 2016 May; 111(5):677-84. PubMed ID: 26977758
[TBL] [Abstract][Full Text] [Related]
34. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease.
Mikolasevic I; Domislovic V; Klapan M; Juric T; Lukic A; Krznaric-Zrnic I; Fuckar-Cupic D; Stimac D; Filipec Kanizaj T; Krznaric Z; Radic-Kristo D; Milic S; Martinovic M; Grubesic A; Grgurevic I
Ultrasound Med Biol; 2021 Mar; 47(3):428-437. PubMed ID: 33358052
[TBL] [Abstract][Full Text] [Related]
36. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
37. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
38. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
39. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
